(VIANEWS) – Shares of BIOSENIC (BEL 20: BIOS.BR) fell by a staggering 30.26% in 21 sessions from €0.19 to €0.13 at 16:09 EST on Monday, following the last session’s downward trend. BEL 20 is jumping 0.53% to €3,622.01, following the last session’s downward trend.
About BIOSENIC
BioSenic S.A., a biotech company, focuses on developing clinical assets. Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company's investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult tibial fractures. The company is based in Mont-Saint-Guibert, Belgium.
Volume
Today’s last reported volume for BIOSENIC is 155755 which is 53.33% below its average volume of 298921.
More news about BIOSENIC (BIOS.BR).
